Ads
related to: latest metastatic prostate cancer treatments- Second Opinion
In Need of a Second Opinion?
Our Cancer Answer Line Can Help
- Prostate Cancer Treatment
Download our Prostate Cancer Guide
Find Prostate Cancer Treatments
- Need a Second Opinion?
Put Our Expertise to Work for You.
Get a Virtual Second Opinion Today.
- Virtual Second Opinions
Get Peace of Mind from Home.
Review Your Diagnosis & Treatment.
- Second Opinion
Search results
Results from the WOW.Com Content Network
Bisphosphonates such as zoledronic acid have been shown to delay skeletal complications such as fractures or the need for radiation therapy in patients with hormone-refractory metastatic prostate cancer. [84] Xofigo is a new alpha-emitting pharmaceutical targeting bone metastasis. Phase II testing shows prolonged patient survival times, reduced ...
The trial investigates new approaches for men with metastatic and locally advanced prostate cancer. [1] 117 hospitals in the UK and Switzerland are involved with over 10,000 men are expected to take part in the trial. [2] The men are randomly assigned to one of a number of "arms". The primary outcome by which the arms were judged is overall ...
New Advancements in Prostate Cancer Treatment RESEARCHERS CONTINUE TO look for new treatments for prostate cancer, and a number of “exciting developments” are in the works, Dr. Siddiqui says.
Prostate tumors were first described in the mid-19th century, during surgeries on men with urinary obstructions. Initially, prostatectomy was the primary treatment for prostate cancer. By the mid-20th century, radiation treatments and hormone therapies were developed to improve prostate cancer treatment.
Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent ...
PROSTVAC is being developed in partnership with the National Cancer Institute under a formal Cooperative Research and Development Agreement and has been the subject of multiple ongoing and completed clinical studies, including the global Phase 3 PROSPECT study underway in patients with asymptomatic or minimally symptomatic metastatic prostate cancer (mCRPC). [2]
Ads
related to: latest metastatic prostate cancer treatments